Other headlines:Infinitt readies new PACS for ACC Abbott’s bioabsorbable stent advances
Siemens Healthcare will unveil a new version of its Artis zeego interventional x-ray system March 29 at the American College of Cardiology meeting in Orlando, FL. The work-in-progress, which is pending FDA clearance, features a small detector designed to boost efficiency and precision. Its 56-inch color screen can be programmed to display the next workflow step directly at the tableside, allowing 12 different screen combinations.
An enterprise-wide image management system for cardiology will debut in the Infinitt North America booth March 29 during ACC 2009. The web-based Infinitt Cardiology PACS features a user-friendly interface, optimized for cardiology. Smart clients support cine CT and provide measurement tools for cardiac cath, echo, noninvasive vascular, ECG, and volumetric CT images. Dual monitors allow side-by-side comparison of images, as well as viewing of images along with the report and thumbnail images that can be enlarged to full screen. Reporting functions include a Cardiac Cath Report Template displaying a coronary tree, Echo Report Template, Non-Invasive Vascular Report Template, Echo Wall Motion Scoring, and a report customization tool with electronic signature, eliminating dictation and transcription.
The next phase of the ABSORB clinical trial to evaluate Abbott's fully bioabsorbable drug-eluting coronary stent has begun. This second phase, designed to enroll approximately 80 patients at 10 centers in Europe, Australia, and New Zealand, will incorporate device enhancements designed to improve deliverability and vessel support. The experimental stent represents the latest generation of interventional cardiology technology, which began more than two decades ago with bare metal stents. Results from the first stage of the trial with 30 patients demonstrated that the bioabsorbable everolimus-eluting stent successfully treated coronary artery disease. At two years, the treated vessel was able to expand and contract without being restricted by a permanent implant, indicating that the device was absorbed. Of the 30 patients, none has yet experienced thrombosis.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.